Minor
DENALI · Azenosertib (ZN-c3) · Platinum-Resistant High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Trial sites reduced: 92 → 86 locations
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, IncPhase 2 NCT05128825 Registry history of NCT05128825 on ClinicalTrials.gov (opens the registry)